Aligos Therapeutics, Inc. Financials
This page shows Aligos Therapeutics, Inc. (ALGS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Aligos Therapeutics, Inc. has an operating margin of -2469.0%, meaning the company retains $-2469 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -1423.5% the prior year.
Aligos Therapeutics, Inc.'s revenue declined 41.7% year-over-year, from $6.2M to $3.6M. This contraction results in a growth score of 0/100.
With a current ratio of 2.86, Aligos Therapeutics, Inc. holds $2.86 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
While Aligos Therapeutics, Inc. generated -$80.7M in operating cash flow, capex of $130K consumed most of it, leaving -$80.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Aligos Therapeutics, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Aligos Therapeutics, Inc. generates $0.62 in operating cash flow (-$80.7M OCF vs -$131.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aligos Therapeutics, Inc. earns $-52.4 in operating income for every $1 of interest expense (-$89.2M vs $1.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Aligos Therapeutics, Inc. generated $3.6M in revenue in fiscal year 2024. This represents a decrease of 41.7% from the prior year.
Aligos Therapeutics, Inc.'s EBITDA was -$88.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.8% from the prior year.
Aligos Therapeutics, Inc. generated -$80.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 2.4% from the prior year.
Aligos Therapeutics, Inc. reported -$131.2M in net income in fiscal year 2024. This represents a decrease of 49.6% from the prior year.
Aligos Therapeutics, Inc. earned $-20.94 per diluted share (EPS) in fiscal year 2024. This represents an increase of 38.8% from the prior year.
Aligos Therapeutics, Inc. held $37.0M in cash against $0 in long-term debt as of fiscal year 2024.
Aligos Therapeutics, Inc. had 4M shares outstanding in fiscal year 2024. This represents an increase of 28.6% from the prior year.
Aligos Therapeutics, Inc.'s operating margin was -2469.0% in fiscal year 2024, reflecting core business profitability. This is down 1045.5 percentage points from the prior year.
Aligos Therapeutics, Inc.'s net profit margin was -3633.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 2217.4 percentage points from the prior year.
Aligos Therapeutics, Inc. invested $70.3M in research and development in fiscal year 2024. This represents a decrease of 3.8% from the prior year.
Aligos Therapeutics, Inc. invested $130K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 584.2% from the prior year.
ALGS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $741K-23.2% | $965K+210.3% | $311K-53.7% | $672K-38.1% | $1.1M-74.7% | $4.3M+2967.1% | $140K | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $23.9M+71.3% | $14.0M-3.6% | $14.5M-34.8% | $22.3M+40.3% | $15.9M-5.4% | $16.8M-7.5% | $18.1M | N/A |
| SG&A Expenses | $5.2M-7.0% | $5.6M+10.0% | $5.1M-21.3% | $6.4M-0.3% | $6.4M-30.3% | $9.2M+8.7% | $8.5M | N/A |
| Operating Income | -$28.4M-52.7% | -$18.6M+3.5% | -$19.2M+26.0% | -$26.0M-36.3% | -$19.1M+0.4% | -$19.1M+20.0% | -$23.9M | N/A |
| Interest Expense | $400K0.0% | $400K-50.0% | $800K-50.0% | $1.6M+60.0% | $1.0M0.0% | $1.0M+42.9% | $700K | N/A |
| Income Tax | $56K-69.7% | $185K+330.2% | $43K+243.3% | -$30K-203.4% | $29K-96.2% | $757K+1841.0% | $39K | N/A |
| Net Income | -$31.5M-98.8% | -$15.9M-136.8% | $43.1M+254.5% | -$27.9M-54.6% | -$18.0M+4.0% | -$18.8M+18.1% | -$23.0M | N/A |
| EPS (Diluted) | $-3.04-98.7% | $-1.53+27.5% | $-2.11+90.8% | $-22.87 | $-10.37-2311.6% | $-0.43+18.9% | $-0.53 | N/A |
ALGS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $109.8M-18.5% | $134.7M-10.6% | $150.7M-0.5% | $151.5M+76.5% | $85.9M-19.1% | $106.1M-12.8% | $121.7M-17.0% | $146.7M |
| Current Assets | $103.4M-19.2% | $127.9M-10.7% | $143.2M+1.5% | $141.1M+89.0% | $74.6M-20.8% | $94.2M-13.9% | $109.4M-18.1% | $133.5M |
| Cash & Equivalents | $41.9M+124.8% | $18.7M-74.7% | $73.8M-45.6% | $135.7M+92.7% | $70.4M-22.5% | $90.8M+15.5% | $78.7M-3.3% | $81.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.9M+15.5% | $32.8M-4.1% | $34.3M-42.4% | $59.4M+91.6% | $31.0M-15.0% | $36.5M-1.3% | $37.0M-13.6% | $42.8M |
| Current Liabilities | $22.0M+8.5% | $20.3M+7.0% | $18.9M-20.7% | $23.9M+6.4% | $22.5M-17.5% | $27.2M-3.0% | $28.1M-15.2% | $33.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $71.8M-29.5% | $101.9M-12.5% | $116.4M+26.5% | $92.1M+68.0% | $54.8M-21.3% | $69.6M-17.8% | $84.8M-18.4% | $103.9M |
| Retained Earnings | -$622.3M-5.3% | -$590.8M-2.8% | -$574.9M-18.1% | -$486.8M-6.1% | -$458.9M-4.1% | -$440.9M-4.5% | -$422.1M-5.8% | -$399.1M |
ALGS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$24.3M-57.0% | -$15.5M+25.9% | -$20.9M+7.7% | -$22.7M-11.4% | -$20.3M-49.4% | -$13.6M+39.2% | -$22.4M-33.4% | -$16.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $7K-92.3% | $91K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$22.4M-32.7% | -$16.9M |
| Investing Cash Flow | $47.7M+221.0% | -$39.4M+10.5% | -$44.1M-629428.6% | -$7K+22.2% | -$9K-100.0% | $25.0M+25.1% | $20.0M+72.3% | $11.6M |
| Financing Cash Flow | -$53K+70.1% | -$177K-100.2% | $101.7M+15.7% | $87.9M+418842.9% | -$21K-105.1% | $414K+41500.0% | -$1K-100.8% | $121K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ALGS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -3827.4%-1903.4pp | -1924.0%+4263.4pp | -6187.5%-2318.9pp | -3868.6%-2110.9pp | -1757.7%-1311.9pp | -445.8%+16638.5pp | -17084.3% | N/A |
| Net Margin | -4256.0%-2612.2pp | -1643.8%-15498.5pp | 13854.7%+18005.3pp | -4150.6%-2487.8pp | -1662.8%-1225.2pp | -437.6%+15958.8pp | -16396.4% | N/A |
| Return on Equity | N/A | 7.5%-29.5pp | 37.0% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -28.7%-16.9pp | -11.8%-40.4pp | 28.6%+47.0pp | -18.4%+2.6pp | -21.0%-3.3pp | -17.7%+1.1pp | -18.9% | N/A |
| Current Ratio | 4.70-1.6 | 6.31-1.2 | 7.56+1.7 | 5.90+2.6 | 3.32-0.1 | 3.46-0.4 | 3.90-0.1 | 4.03 |
| Debt-to-Equity | 0.53+0.2 | 0.32+0.0 | 0.29-0.4 | 0.65+0.1 | 0.57+0.0 | 0.52+0.1 | 0.44+0.0 | 0.41 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -15995.7% | N/A |
Note: Shareholder equity is negative (-$29.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Aligos Therapeutics, Inc.'s annual revenue?
Aligos Therapeutics, Inc. (ALGS) reported $3.6M in total revenue for fiscal year 2024. This represents a -41.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aligos Therapeutics, Inc.'s revenue growing?
Aligos Therapeutics, Inc. (ALGS) revenue declined by 41.7% year-over-year, from $6.2M to $3.6M in fiscal year 2024.
Is Aligos Therapeutics, Inc. profitable?
No, Aligos Therapeutics, Inc. (ALGS) reported a net income of -$131.2M in fiscal year 2024, with a net profit margin of -3633.7%.
What is Aligos Therapeutics, Inc.'s earnings per share (EPS)?
Aligos Therapeutics, Inc. (ALGS) reported diluted earnings per share of $-20.94 for fiscal year 2024. This represents a 38.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Aligos Therapeutics, Inc.'s EBITDA?
Aligos Therapeutics, Inc. (ALGS) had EBITDA of -$88.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aligos Therapeutics, Inc.'s operating margin?
Aligos Therapeutics, Inc. (ALGS) had an operating margin of -2469.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Aligos Therapeutics, Inc.'s net profit margin?
Aligos Therapeutics, Inc. (ALGS) had a net profit margin of -3633.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Aligos Therapeutics, Inc.'s free cash flow?
Aligos Therapeutics, Inc. (ALGS) generated -$80.9M in free cash flow during fiscal year 2024. This represents a -2.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aligos Therapeutics, Inc.'s operating cash flow?
Aligos Therapeutics, Inc. (ALGS) generated -$80.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aligos Therapeutics, Inc.'s total assets?
Aligos Therapeutics, Inc. (ALGS) had $70.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Aligos Therapeutics, Inc.'s capital expenditures?
Aligos Therapeutics, Inc. (ALGS) invested $130K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Aligos Therapeutics, Inc. spend on research and development?
Aligos Therapeutics, Inc. (ALGS) invested $70.3M in research and development during fiscal year 2024.
How many shares does Aligos Therapeutics, Inc. have outstanding?
Aligos Therapeutics, Inc. (ALGS) had 4M shares outstanding as of fiscal year 2024.
What is Aligos Therapeutics, Inc.'s current ratio?
Aligos Therapeutics, Inc. (ALGS) had a current ratio of 2.86 as of fiscal year 2024, which is generally considered healthy.
What is Aligos Therapeutics, Inc.'s debt-to-equity ratio?
Aligos Therapeutics, Inc. (ALGS) had a debt-to-equity ratio of -3.42 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aligos Therapeutics, Inc.'s return on assets (ROA)?
Aligos Therapeutics, Inc. (ALGS) had a return on assets of -187.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aligos Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Aligos Therapeutics, Inc. (ALGS) had $37.0M in cash against an annual operating cash burn of $80.7M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aligos Therapeutics, Inc.'s debt-to-equity ratio negative or unusual?
Aligos Therapeutics, Inc. (ALGS) has negative shareholder equity of -$29.0M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aligos Therapeutics, Inc.'s Piotroski F-Score?
Aligos Therapeutics, Inc. (ALGS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aligos Therapeutics, Inc.'s earnings high quality?
Aligos Therapeutics, Inc. (ALGS) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aligos Therapeutics, Inc. cover its interest payments?
Aligos Therapeutics, Inc. (ALGS) has an interest coverage ratio of -52.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aligos Therapeutics, Inc.?
Aligos Therapeutics, Inc. (ALGS) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.